Papers: 28 May 2012 - 4 Jun 2012
The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α
Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis.
Effect of short-term interferon-β treatment on cytokines in multiple sclerosis: Significant modulation of IL-17 and IL-23.
Long term benefit of multiple sclerosis treatment: an investigation using a novel data collection technique.
CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation.
Estimated incidence of multiple sclerosis among United States Armed Forces personnel using the Defense Medical Surveillance System.
The Treatment experience, burden, and unmet needs (TRIBUNE) study - measuring the socioeconomic consequences of Multiple Sclerosis.
Viability of autoantibody-targets: How to tackle pathogenetic heterogeneity as an obstacle for treatment of multiple sclerosis.
Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries.
Cutting Edge: TNF Receptor-Associated Factor 4 Restricts IL-17-Mediated Pathology and Signaling Processes.
Using experimental autoimmune encephalomyelitis as a model to study the effect of prenatal stress on fetal programming.
Severe liver dysfunction possibly caused by the combination of interferon beta-1b therapy and melilot (sweet clover) supplement.
Using magnetic resonance imaging as a means to study chronic cerebral spinal venous insufficiency in multiple sclerosis patients.
[Translation and cross-cultural adaptation of the Multiple Sclerosis Walking Scale (MSWS-12) into Brazilian Portuguese].
Cerebrospinal Fluid BAFF and APRIL Levels in Neuromyelitis Optica and Multiple Sclerosis Patients During Relapse.
Non-lesional white matter changes in pediatric multiple sclerosis and monophasic demyelinating disorders.
A serial in vivo 7T magnetic resonance phase imaging study of white matter lesions in multiple sclerosis.
Genetic inactivation of the adenosine A(2A) receptor exacerbates brain damage in mice with experimental autoimmune encephalomyelitis.
Th17 Cells: Biology, Pathogenesis of Autoimmune and Inflammatory Diseases, and Therapeutic Strategies.
siRNA knockdown of ADAM-10, but not ADAM-17, significantly reduces fractalkine shedding following pro-inflammatory cytokine treatment in a human adult brain endothelial cell line.
Isolated trigeminal nerve palsy with motor involvement as a presenting manifestation of multiple sclerosis in an equatorial region - a case report.
Internet-based social networking and its role in the evolution of chronic cerebrospinal venous insufficiency.
The Brown Norway opticospinal model of demyelination: Does it mimic multiple sclerosis or neuromyelitis optica?
Decreased serum levels of nucleolin protein fragment, as analyzed by bead-based proteomic technology, in multiple sclerosis patients compared to controls.
Lack of response to rituximab therapy in patients with neuromyelitis optica: True non-responders or insufficient treatment?
The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis.
Immunopathological patterns from EAE and Theiler's virus infection: Is multiple sclerosis a homogenous 1-stage or heterogenous 2-stage disease?
The Stigma Scale for Chronic Illnesses 8-Item Version (SSCI-8): Development, Validation and Use Across Neurological Conditions.
Durable pharmacological responses from the peptide drug ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.
Comparative validity of accelerometer based measures of physical activity for people with multiple sclerosis.
Lack of response to rituximab therapy in patients with neuromyelitis optica: Response to Kim and Kim.
[Sacral neuromodulation as second-line treatment strategy for lower urinary tract symptoms of various aetiologies: experience of a german high-volume clinic].